Cellcentric

Developer of oral small molecule inhibitors for treating blood cancers

placeCambridge, England, United Kingdom calendar_todayFounded 2003 groups18 employees language cellcentric.com

Registered entities

Innovation

6 patent families (6 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 634 times.

YearFilings
20131
20141
20162
20184
20194
20203
20214
20224
20231
20242
20252
20261

Social engagement

Social engagement: 6.6K social following, 5 posts in the last 12 months — below the industry typical range.

Investor mix

52 investors on record; lead investors include Takeda Ventures, Morningside, Nesta Impact Investments, Morningside.

Investor typeCountShare
Venture capital1121%
Private equity24%
Other / undisclosed3975%

Recent activity

8 Jun 2026
Leadership hire
Chief Administrative Officer and U.S. General Counsel
4 Jun 2026
Event
EHA2026
27 May 2026
Product launch
mminovation.com
Coming soon